Love the Q3 results. Most impressed by the 42% month on month rev increase. have to think that this will slow down however as an increase at this rate month on month would lead to nearly 5.5m rev for Q4!
You left out one critical item which was bothering me. The reason for the need to increase the number of shares. They needed to cover the obligations to the stockholders of the company the acquired when and if Fluticare gets FDA approval.
The current battle is still with the MM's and companies like NITE. I will be very interested in the short interest for the next two months to see whether it is going up or will continue down. 2 reports ago, the short interest had climed. Last month the short interest declined. This month may be little change so the most informative month will be the short interest which comes out after the 15th of December.
If the short interest is dropping, that is a strong keep buying signal.